{
  "data": {
    "indicator": {
      "slug": "new-medicines-availability-rate",
      "name": "New medicines availability rate",
      "definition": "Percentage of newly approved medicines made fully accessible for their licensed indications.",
      "unit": "percent",
      "scale": "1",
      "default_unit": "percent",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "percent",
    "region": {
      "code": "GB",
      "name": "United Kingdom",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2021-01-01",
        "period_label": "2021–2024",
        "value": 33,
        "scale": "1",
        "unit": "percent",
        "value_type": "actual",
        "statistic_id": "stat_TBT0EHZB6AJK58HZ51FA8ABSBW",
        "url": "https://statorigin.org/stat/stat_TBT0EHZB6AJK58HZ51FA8ABSBW",
        "source_org": "ABPI",
        "source": {
          "org": "Association of the British Pharmaceutical Industry",
          "org_short_name": "ABPI",
          "document_title": "Green shoots for UK pharma investment, but delivery will decide whether they take root",
          "document_url": "https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/",
          "locator": "UK competitive weaknesses",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GB"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}